Science Updates

CRISPR-Edited TIL Therapy Targets New Intracellular Checkpoint, Shows Promise in Treatment-Resistant GI Cancers

Clinical Benefit of a Combination of Ipilimumab and Nivolumab in Treatment-Naïve Patients with Advanced or Metastatic Non-Clear Cell RCC

NK Cells Complexed With Bispecific Antibody May Be of Benefit to Patients With Lymphoma

Neoadjuvant Combination Immunotherapy for Head and Neck Cancer

Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study

Neoadjuvant Durvalumab Plus Chemotherapy for High-Risk Upper-Tract Urothelial Carcinoma

FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer

Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-Cell ALL of Average or High Risk of Relapse

FDA Pipeline: Agents in DLBCL, SCLC, AML, and More